Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Svea Ekonomi in connection with acquisition of Payson
Mandate

Vinge advises Svea Ekonomi in connection with acquisition of Payson

July 02, 2012

Vinge has advised Svea Ekonomi in connection with the acquisition of the payment services company, Payson AB. Following the acquisition, Svea Ekonomi will be able to offer several online payment services to corporate customers and private individuals. Payson launched its online service in 2004 and is currently one of Sweden’s leading actors in this area with more than 5 000 online stores and almost 2 000 accounts for private individuals. Payson and Svea Ekonomi’s existing services within online payments, SveaWebPay, will have an aggregate turnover of approximately SEK 100 from day one. The acquisition of Payson is subject to the consent of the Swedish Financial Supervisory Authority.

Vinge’s team consisted of Mikael Ståhl, Johan Larsson, Louise Brorsson Salomon and Jonas Johansson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026